Feb 18 (Reuters) - Supernus Pharmaceuticals Inc SUPN.O:
SUPERNUS ANNOUNCES TOPLINE RESULTS FROM PHASE 2B STUDY IN ADULTS WITH TREATMENT RESISTANT DEPRESSION
SUPERNUS PHARMACEUTICALS INC - PHASE 2B STUDY OF SPN-820 IN TRD FAILS PRIMARY ENDPOINT
SUPERNUS PHARMACEUTICALS INC - SPN-820 SAFETY PROFILE CONSISTENT WITH PREVIOUS TRIALS
Source text: ID:nGNX7YJMG2
Further company coverage: SUPN.O